Literature DB >> 1259402

In vitro activity, synergism, and testing parameters of amikacin, with comparisons to other aminoglycoside antibiotics.

M T Kelly, J M Matsen.   

Abstract

The activity of the new aminoglycoside antibiotic, amikacin, was evaluated in vitro against 219 clinical bacterial isolates. One hundred eighty-nine of the 219 strains had agar dilution minimal inhibitory concentration values of 8.0 mug/ml or less for amikacin. Comparative agar dilution studies were performed for gentamicin, kanamycin, and tobramycin. Gentamicin was the most active overall, but tobramycin and amikacin also had significant activity against most bacterial groups. The effects of divalent cations on the susceptibility of Pseudomonas aeruginosa to amikacin were evaluated, and the minimal inhibitory concentration values varied sixfold over a range of divalent cation concentrations from 0.2 to 8.75 mg%. The effects of media and inoculum size on disk susceptibility testing with amikacin were also evaluated. In addition, a synergistic interaction between carbenicillin and amikacin against P. aeruginosa was demonstrated. Amikacin appears to be a promising new broad spectrum antimicrobial agent.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1259402      PMCID: PMC429549          DOI: 10.1128/AAC.9.3.440

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  BB-K 8, a new semisynthetic aminoglycoside antibiotic.

Authors:  H Kawaguchi; T Naito; S Nakagawa; K I Fujisawa
Journal:  J Antibiot (Tokyo)       Date:  1972-12       Impact factor: 2.649

2.  In vitro studies of BB-K8, a new aminoglycoside antibiotic.

Authors:  G P Bodey; D Stewart
Journal:  Antimicrob Agents Chemother       Date:  1973-08       Impact factor: 5.191

3.  A virulent nosocomial Klebsiella with a transferable R factor for gentamicin: emergence and suppression.

Authors:  C M Martin; N S Ikari; J Zimmerman; J A Waitz
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

4.  Colonization with gentamicin-resistant Pseudomonas aeruginosa, pyocine type 5, in a burn unit.

Authors:  J A Shulman; P M Terry; C E Hough
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

5.  Amikacin (BB-K8) treatment of multiple-drug resistant Proteus infections.

Authors:  P M Sharp; C A Saenz; R R Martin
Journal:  Antimicrob Agents Chemother       Date:  1974-05       Impact factor: 5.191

6.  Activity of BB-K8 (amikacin) against clinical isolates resistant to one or more aminoglycoside antibiotics.

Authors:  K E Price; T A Pursiano; M D DeFuria
Journal:  Antimicrob Agents Chemother       Date:  1974-02       Impact factor: 5.191

7.  Comparative in vitro activity of three aminoglycosidic antibiotics: BB-K8, kanamycin, and gentamicin.

Authors:  P K Yu; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1973-08       Impact factor: 5.191

8.  In vitro effects of carbenicillin combined with gentamicin or polymyxin B against Pseudomonas aeruginosa.

Authors:  T C Eickhoff
Journal:  Appl Microbiol       Date:  1969-09

9.  Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus.

Authors:  L S Young; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1973-12       Impact factor: 5.191

10.  In vitro evaluation of a new aminoglycoside derivative of kanamycin, a comparison with tobramycin and gentamycin.

Authors:  K Ries; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

View more
  13 in total

1.  The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination.

Authors:  Kenneth P Smith; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

2.  Emergence in a burn center of populations of bacteria resistant to gentamicin, tobramycin, and amikacin: evidence for the need for changes in zone diameter interpretative standards.

Authors:  B H Minshew; H M Pollock; F D Schoenknecht; J C Sherris
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

3.  Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis.

Authors:  L Regeur; H Colding; H Jensen; J P Kampmann
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

4.  Early synergistic interactions between amikacin and six beta-lactam antibiotics against multiply resistant members of the family Enterobacteriaceae.

Authors:  R H Glew; R A Pavuk
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

Review 5.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

6.  Decreased susceptibility to 4'-deoxy-6'-N-methylamikacin (BB-K311) conferred by a mutant plasmid in Escherichia coli.

Authors:  M H Perlin; S A Lerner
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

7.  In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.

Authors:  S H Zinner; J Klastersky; H Gaya; C Bernard; J C Ryff
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

8.  Amikacin and cephalothin: empiric regimen for granulocytopenic cancer patients.

Authors:  D M Hahn; S C Schimpff; V M Young; C L Fortner; H C Standiford; P H Wiernik
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

9.  Amikacin resistance associated with a plasmid-borne aminoglycoside phosphotransferase in Escherichia coli.

Authors:  M H Perlin; S A Lerner
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

10.  Microdilution transfer plate technique for determining in vitro synergy of antimicrobial agents.

Authors:  P F Dougherty; D W Yotter; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.